Building better chimeric antigen receptors for adoptive T cell therapy.
AffiliationCellular Therapy Group, Cancer Research UK Department of Medical Oncology, Paterson Institute for Cancer Research, Manchester, UK.
MetadataShow full item record
AbstractThe last few years have seen the transfer of two decades of research into Chimeric Antigen Receptors (CARs) into clinical trials. Despite this extensive research, there is still a great deal of debate into the optimal design strategy for these, primarily, anti-cancer entities. The archetypal CAR consists of a single-chain antibody fragment, specific to a tumour-associated antigen, fused to a component of the T-cell receptor complex (typically CD3zeta) which on antigen binding primes the engrafted T-cell for anti-tumour activity. The modular nature of these artificial receptors has enabled researchers to modify aspects of their structure, including the extracellular spacer, transmembrane and cytoplasmic domain, to achieve laboratory defined optimal activity. Despite this there is no consensus on the optimal structure, a problem exacerbated by conflicting results using identical receptors. In this review, we provide a structural overview of CAR development and highlight areas that require further refinement. We also attempt to identify possible reasons for conflicting results in the hope that this information will inspire future rational design strategies for optimal tumour targeting using CARs.
CitationBuilding better chimeric antigen receptors for adoptive T cell therapy. 2010, 10 (2):77-90 Curr Gene Ther
JournalCurrent Gene Therapy
- Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.
- Authors: Shi H, Sun M, Liu L, Wang Z
- Issue date: 2014 Sep 21
- T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
- Authors: Jamnani FR, Rahbarizadeh F, Shokrgozar MA, Mahboudi F, Ahmadvand D, Sharifzadeh Z, Parhamifar L, Moghimi SM
- Issue date: 2014 Jan
- CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy.
- Authors: Bridgeman JS, Ladell K, Sheard VE, Miners K, Hawkins RE, Price DA, Gilham DE
- Issue date: 2014 Feb
- Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
- Authors: Han X, Cinay GE, Zhao Y, Guo Y, Zhang X, Wang P
- Issue date: 2017 Nov 1
- Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.
- Authors: Curran KJ, Pegram HJ, Brentjens RJ
- Issue date: 2012 Jun